Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies Life Science
Citryll Completes First Closing of a € 15M Series A to Develop its NETosis Inhibiting Antibody Life Science